EN
Tumour Organoid
Drug Sensitivity Test
A new way to guide personalised treatment.
What is Tumour Organoid Drug Sensitivity Test?
Tumour Organoid Drug Sensitivity Test uses proprietary organoid technology to test how the patient’s tumour cells respond to a panel of oncology drugs in their tumour organoids. Since tumour organoid physiologically and genetically simulates the original tumour, the drug testing results will assist the medical practitioner in formulating personalized treatment strategies.
How it Works
Biopsy & Tissue Collection
A small portion of the patient’s tumour tissue is collected during surgery or a routine biopsy. Malignant body fluid is also acceptable.
Growing Tumour Organoids
The patient’s tumour organoids are grown in the laboratory and prepared for drug testing.
Testing Drug Responses
The grown tumour organoids are exposed to various cancer drugs in culture, and their response to each drug is measured in the laboratory.
Delivering Personalized Treatment Insights
A report summarizing the tumour organoid drug sensitivity is shared with the oncologist, who will review it alongside the patient’s clinical history to help guide a personalized treatment plan.
Tumour Organoid Drug Sensitivity Test Report
Patient ID
The Tumour Organoid Drug Sensitivity Test Report summarizes your tumour organoids responses to the drugs tested and provides information to support treatment planning. Your oncologist will review these results alongside your clinical history when planning your treatment.
Sample Report
DIAGNOSIS
Colorectal Cancer
SPECIMEN Type
Resected Tumour
Collection Date
16 Jul 2025
Drug Response Summary
No.
Drugs
Imaging
Response
Interpretation
1
5-Fluorouracil (5-FU)
37.7%
Low Sensitivity
2
Carboplatin
13.2%
Resistant
3
Docetaxel
47.1%
Low Sensitivity
4
Everolimus
24.1%
Resistant
5
Gemcitabine
53.5%
Intermediate
6
Irinotecan
31.6%
Low Sensitivity
7
Oxaliplatin
11.4%
Resistant
8
Paclitaxel
50.2%
Intermediate
Advancing Clinically Aligned Insights
Predictive Accuracy
The "Tumour Avatar" closely reflects each patient’s drug response, bridging the gap between genetic profiling and real‑world functional outcomes.
Reduced Toxicity
Identify the most effective therapies while avoiding ineffective ones, reducing unnecessary exposure to side effects and toxicity.
Faster Therapeutic Intervention
Our optimized screening process provides actionable insights within clinically relevant timelines, enabling faster treatment decisions.
Applications Across Solid Tumours
GI Cancers
Lung Cancer
Optimizing chemotherapy and targeted regimens for colorectal, gastric, and pancreatic malignancies via patient-specific drug response profiling.
Evaluating standard-of-care and novel TKI responses in NSCLC, bridging the gap between genomic data and functional outcomes.
Breast Cancer
Other Solid Tumours
Refining therapeutic selection for TNBC and advanced cases, including sensitivity testing for ADCs.
Providing evidence‑based phenotypic insights for other solid tumours, including head and neck cancers, esophageal cancer, liver cancer, bladder cancer, sarcoma, and others.